目的 旨在通过分析一例临床药师参与的多发性骨髓瘤患者在接受硼替佐米化疗后出现周围神经病变的病例,研究其发病机制及治疗过程。方法 通过对多个数据库的系统检索和广泛查找文献数据库,深入分析硼替佐米致周围神经病变的发病机制和危险因素。结果 结合患者的查体、血常规检查、生化检查、病史和症状等多方面信息,对多发性骨髓瘤致周围神经病变的个体化治疗方案进行了临床分析和整体药学监护计划。临床医生采纳临床药师的建议并付诸实践,患者的药源性周围神经病变得到了改善。结论 硼替佐米在多发性骨髓瘤患者中引起的周围神经病变是其不良反应,但是它是可以治疗和逆转的。通过及时调整用药方案,可明显的减轻或延缓患者的症状和病情,甚至使其消失。在治疗过程中,临床药师的参与起到了积极的作用,协助医师制定了更加个体化的治疗方案,为患者的安全、有效和合理用药提供了有力的支持。

Objective: This study aims to investigate the case of peripheral neuropathy in a patient with multiple myeloma undergoing bortezomib chemotherapy, with the involvement of a clinical pharmacist. The study focuses on understanding the pathogenesis and treatment process. Methods: Systematic searches across multiple databases and extensive literature review were conducted to analyze the pathogenesis and risk factors of bortezomib-induced peripheral neuropathy. Patient-specific treatment plans for peripheral neuropathy in multiple myeloma were clinically analyzed, considering physical examination, blood tests, biochemical assessments, medical history, and symptoms. A comprehensive pharmaceutical care plan was devised. Results: Combining information from the patient"s physical examination, routine blood tests, biochemical assessments, medical history, and symptoms, an individualized treatment plan for bortezomib-induced peripheral neuropathy in multiple myeloma was clinically analyzed. Clinical pharmacists actively participated in the development of a personalized pharmaceutical care plan, which, when implemented by clinicians, led to the improvement of the patient"s drug-induced peripheral neuropathy. Conclusion: Peripheral neuropathy induced by bortezomib in patients with multiple myeloma is an adverse reaction that can be treated and reversed. Through timely adjustments to the medication regimen, symptoms and the progression of the disease in the patient can be significantly alleviated or delayed, and in some cases, even reversed. The involvement of clinical pharmacists in the treatment process plays a crucial role by assisting physicians in formulating more personalized treatment plans, providing robust support for the safe, effective, and rational use of medication for the patient.

国家自然科学(82160703)、内蒙古自治区自然科学(2020MS08106)